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Endocarditis in the
United StatesThe paper by Pant et al. (1) and the editorial by Dayer
and Thornhill (2) provided further insight into
the recent pattern of endocarditis hospitalizations in
the United States, and the potential causes behind the
changes. However, we have several concerns about
the paper and the associated editorial. Whereas Pant
et al. (1) declared, “There is scant data on IE trends
since this major practice change in the United States,”
we had published an article in the Journal on the
same topic in 2013 (3), which was unfortunately
missed by Pant et al.
Further, Pant et al. (1) provided subgroup results
stratiﬁed by the potential causative organisms. How-
ever, although potentially interesting, the limitations
of this analysis need highlighting. As appropriately
indicated by Dayer and Thornhill (2), the codes used
by Pant et al. (1) are likely inadequate for diagnosing
organisms. Although using discharge diagnosis codes
for endocarditis has been previously validated against
the Duke criteria (4,5), we are unaware of validation
studies for organism codes used by Pant et al. (1).
Whereas they show an increase in staphylococcal and
streptococcal endocarditis, it is unclear whether it is
due to better diagnostics, change in the coding pat-
terns, double counting the same patients, a real surge
in disease occurrence, or a mix of these. The fact that
there has been an increase in gram-negative, staphy-
lococcal, streptococcal, and fungal endocarditis raises
our suspicion for better diagnostics, or change in
coding patterns; at least as partial contributors.
We should also clarify that the study by Pant et al.
(1), similar to ours, was not a study of true incidence,
but one that determined the hospitalization rates.
Our study is also misrepresented in the editorial by
Dayer and Thornhill (2). They state: “Bikdeli et al.
looked at admissions of patients older than 65 years
by using Medicare inpatient Standard Analytic
Files. They recorded a reduction in the absolute
numbers, but no correction was made for the absolute
numbers of patients enrolled in Medicare eligible fortreatment.” We are surprised by this comment,
because as could be inferred from our paper, even the
title, we had determined the trends in hospitalization
rates, not merely number of hospitalizations.Behnood Bikdeli, MD
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in the United StatesWe would like to thank Dr. Bikdeli and colleagues for
their interest in our paper (1). We do apologize for not
citing the work by Bikdeli et al. (2) on the trends in
hospitalization rates and outcomes of endocarditis
among Medicare beneﬁciaries (1). The difference in
results seen in our paper from the Bikdeli et al. (2)
paper could be because of differences in study pop-
ulation and follow-up duration. We acknowledge the
potential limitation related to coding that could in-
ﬂuence the results of our study as well as other
retrospective studies done on this topic, as pointed
out by Bikdeli et al. (2). Hence, the conclusions made
from the observational studies should be considered
as “hypothesis generating” and not a “causal rela-
tionship.” Prospective studies providing insight into
the impact of the guideline is indeed lacking, and
we have echoed the dire need for such study, which
has been emphasized in the accompanying editorial
by Dayer and Thornhill (3). Nonetheless, a common
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1848theme that can be derived from our study and the
study by Bikdeli et al. (2) is that the burden of infec-
tive endocarditis hospitalization rates in the United
States is high and rising, which ultimately confers
to higher health care expenditure and morbidity.
Hence, a multispecialty collaborative effort is needed
to understand the factors responsible and identify the
strategies to halt this rising trend. We believe that
the ongoing monitoring of the impact of the prophy-
laxis guidelines and appropriate updates on the basis
of such data is an essential step in this regard.Sadip Pant, MD
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Risk During the Statin Era?The Schwartz et al. (1) paper reported that among
patients with acute coronary syndrome treated
effectively with statins, fasting triglycerides (Tg)
predict long-term and short-term cardiovascular risk.
Triglyceride-rich lipoproteins may be an important
additional target for therapy (1).
Lowering low-density lipoprotein cholesterol
(LDL-C) is the primary target in the management of
dyslipidemia in patients at high risk of cardiovas-
cular disease. However, patients who have achieved
LDL-C levels below the currently recommended
targets may still experience cardiovascular events.
This may result, in part, from elevated Tg levels (2).
Atherogenic dyslipidemia, characterized by high Tg,low levels of high-density lipoprotein cholesterol
(HDL-C), and small, dense LDL particles, is a typical
phenotype of dyslipidemia in subjects with insulin
resistance and metabolic syndrome. On the other
hand, raised Tg concentrations are strongly associ-
ated with low concentrations of HDL-C, and the past
15 years have been dominated by HDL research, with
less focus on Tg. However, the understanding from
genetic studies and randomized trials that low HDL-C
might not be a cause of cardiovascular disease as
originally thought has generated renewed interest in
raised Tg (3). Indeed, a study investigated the causal
role of HDL-C and Tg using multiple instrumental
variables for Mendelian randomization and reported
that the genetic ﬁndings supported a causal effect of
Tg on coronary heart disease risk (4).
It is obvious that statins are the ﬁrst-line drug for
the treatment of dyslipidemia. However, a strategy
to reduce high Tg and modify the small, dense
LDL particles is required. In this regard, statin-based
combined with ﬁbrates, peroxisome proliferator-
activated receptor agonists may be recommended in
addition to therapeutic lifestyle changes if patients
still experience cardiovascular events. The cost
effectiveness of these combinations should also be
evaluated (5).*Kwang Kon Koh, MD, PhD
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